Case Study: Groundbreaking Progress in Cord Blood Therapy for Sickle Cell Disease

Sickle cell disease (SCD) is a genetic blood disorder that can have severe and life-threatening complications. It occurs when a child inherits two abnormal genes, one from each parent, leading to the formation of misshapen red blood cells that cause blockages in blood vessels. While treatments for SCD are limited, exciting advancements in cord blood therapies are offering new hope for those affected by this condition, especially within African American and Hispanic American communities, where the disease is more prevalent.

Understanding Sickle Cell Disease and Its Impact

Sickle cell disease causes red blood cells, which are usually flexible and disk-shaped, to become rigid and curved like a crescent or sickle. These sickle-shaped cells can clump together, blocking blood flow and oxygen delivery to organs and tissues, leading to severe pain, infections, strokes, and organ failure. Over time, these complications worsen, especially as individuals reach adolescence and adulthood.

‍

‍

Who Is Affected by Sickle Cell Disease?

Sickle cell disease affects approximately 100,000 Americans, but it disproportionately impacts certain ethnic groups, particularly those with African, Hispanic, and Mediterranean ancestry. It is most common in:

• 1 in 365 Black or African American births
• 1 in 16,300 Hispanic American births
• 1 in 13 Black or African American babies are born with the sickle cell trait (SCT), meaning they carry the gene and could pass it on to future generations.

Cord Blood: A Game-Changer for Sickle Cell Treatment

Finding a matching bone marrow donor can be a challenge, especially for unrelated donors. However, cord blood from a sibling offers a more viable solution. Once a child is born with sickle cell disease or the trait, subsequent children have a 75% chance of not inheriting the disease, making their cord blood an ideal source for treatment.

Recent studies have shown that cord blood transplants from sibling donors offer significant advantages. A large-scale analysis involving 1,000 patients with an average age of nine found a three-year survival rate of 99% for those who received sibling cord blood transplants. This was significantly higher than the survival rates for bone marrow (94%) and peripheral blood (80%) transplants.

These findings are supported by earlier studies from the National Institutes of Health (NIH). One such study, led by Dr. Matthew Hsieh, demonstrated that adults with sickle cell disease can successfully undergo cord blood-like transplants. This research dispelled the previous belief that adults were too likely to reject stem cell transplants due to their increased toxicity risk. With the right treatment protocols, the study achieved impressive success rates in adult patients.

‍

‍

The Importance of Cord Blood Banking

For families affected by sickle cell disease, the most promising treatment is a sibling’s cord blood. With the highest survival rates among all stem cell sources, cord blood transplants are a breakthrough treatment for SCD. Cord blood banking, particularly among African American and Hispanic American families, becomes even more crucial as it offers the best chance of finding a matching donor and potentially curing sickle cell disease. This exciting advancement continues to bring new hope for a condition that has long impacted so many lives.

Anja Health is dedicated to making cord blood banking accessible and affordable for families, helping ensure that life-saving treatments are within reach.

Source: https://www.cryo-cell.com/blog/july-2014/sickle-cell-anemia-treatment-cord-blood#:~:text=The

‍